Selection and Prioritization of Antiviral Drugs used for Hepatitis C Virus (HCV) and evaluation of their efficacy and safety in COVID- 19 Patients: A Rational target- based Pilot Repurposing Trial - SPARTACOS-19 trial

Pt B D Sharma post graduate institute of medical sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•Pregnancy or breast feeding
•Hepatic cirrhosis
•Alanine aminotransferase or aspartate aminotransferase more than five times the upper limit of normal
•Known severe renal impairment (estimated glomerular filtration rate <30 mL/min per 1Â·73 m2) or receipt of continuous renal replacement therapy, haemodialysis, or peritoneal dialysis
•Enrolment into an investigational treatment study for COVID-19 in the 30 days before screening
•Patients of child-bearing age (men and women) not agreeing to take effective contraceptive measures (including hormonal contraception, barrier methods, or abstinence) during the study period and for at least 7 days after the last study drug administration
•Any known hypersensitivity to the study drugs
•Any patient belonging to Severe class of COVID19 disease as per GOI guidelines (MoHFW)

发起方

Pt B D Sharma post graduate institute of medical sciences